The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis

TGF-β/Smad signaling UCHL5 apoptosis bAP15 ovarian cancer

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
15 Oct 2019
Historique:
received: 13 05 2019
accepted: 10 09 2019
entrez: 1 11 2019
pubmed: 2 11 2019
medline: 2 11 2019
Statut: epublish

Résumé

The ubiquitin-proteasome pathway plays an important role in the regulation of cellular proteins. As an alternative to the proteasome itself, recent research has focused on methods to modulate the regulation of deubiquitinating enzymes (DUBs) upstream of the proteasome, identifying DUBs as novel therapeutic targets in breast, endometrial, and prostate cancers, along with multiple myeloma. bAP15, an inhibitor of the 19S proteasome DUBs UCHL5 and USP14, results in cell growth inhibition in several human cancers; however, the mechanism remains poorly understood in ovarian cancer. Here, we found that aberrant UCHL5 expression predicted shorter progression-free survival (PFS) in a cohort of 1435 patients with ovarian cancer described in the Gene Expression Omnibus and The Cancer Genome Atlas databases. The subgroup of patients with

Identifiants

pubmed: 31666925
doi: 10.18632/oncotarget.27219
pii: 27219
pmc: PMC6800272
doi:

Types de publication

Journal Article

Langues

eng

Pagination

5932-5948

Informations de copyright

Copyright: © 2019 Fukui et al.

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.

Références

Eur J Pharmacol. 2018 Apr 15;825:10-18
pubmed: 29454609
J Obstet Gynaecol Res. 2015 May;41(5):755-62
pubmed: 25421004
Cell. 2010 Nov 24;143(5):686-93
pubmed: 21111230
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Nat Rev Drug Discov. 2018 Jan;17(1):57-78
pubmed: 28959952
Nat Commun. 2013;4:2519
pubmed: 24071738
J Biol Chem. 2011 Nov 25;286(47):40520-30
pubmed: 21931165
Oncogene. 2018 Apr;37(14):1896-1910
pubmed: 29353883
Future Med Chem. 2018 Sep 1;10(17):2087-2108
pubmed: 30066579
Oncologist. 2002;7(1):9-16
pubmed: 11854543
Tumour Biol. 2017 Jul;39(7):1010428317716078
pubmed: 28681694
Oncogene. 2005 Dec 1;24(54):8080-4
pubmed: 16027725
Cell Res. 2016 Apr;26(4):399-422
pubmed: 27012465
Mol Cancer Ther. 2019 Jun;18(6):1045-1056
pubmed: 30962318
Int J Biochem Cell Biol. 2012 Nov;44(11):1729-38
pubmed: 22819849
Mol Pharmacol. 2014 Jun;85(6):932-45
pubmed: 24714215
Tumour Biol. 2017 Jun;39(6):1010428317710411
pubmed: 28653876
Dig Dis Sci. 2012 Sep;57(9):2310-7
pubmed: 22615012
Front Genet. 2016 Jul 28;7:133
pubmed: 27516771
Int Immunol. 2016 Jul;28(7):339-48
pubmed: 27055470
Int J Mol Sci. 2017 Jul 30;18(8):null
pubmed: 28758950
Oncotarget. 2015 Feb 28;6(6):4159-70
pubmed: 25784654
Curr Protoc Pharmacol. 2009 Jun;Chapter 14:Unit14.12
pubmed: 22294392
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
Blood. 2014 Jan 30;123(5):706-16
pubmed: 24319254
Oncotarget. 2017 Jun 28;8(38):63232-63246
pubmed: 28968984
Lancet. 2010 Jul 24;376(9737):245-51
pubmed: 20609468
Nat Med. 2012 Feb 19;18(3):429-35
pubmed: 22344298
Cancer Res. 2006 Apr 1;66(7):3754-63
pubmed: 16585202
Open Biol. 2012 Jun;2(6):120063
pubmed: 22773947
Science. 2013 Feb 1;339(6119):590-5
pubmed: 23287719
Int J Gynecol Cancer. 2016 Jun;26(5):839-44
pubmed: 27051056
Oncotarget. 2017 Feb 14;8(7):12389-12405
pubmed: 27852039
Oncotarget. 2016 May 24;7(21):30962-76
pubmed: 27121063
PLoS One. 2018 Feb 23;13(2):e0193125
pubmed: 29474458
Tumour Biol. 2014 Nov;35(11):11427-33
pubmed: 25123264
Biochim Biophys Acta. 2013 Mar;1833(3):559-72
pubmed: 23220010
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Cell Biol. 2012 Jun 17;14(7):717-26
pubmed: 22706160
Clin Cancer Res. 2013 Sep 1;19(17):4559-63
pubmed: 23775332
Oncotarget. 2015 May 30;6(15):12872-89
pubmed: 25972356
J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17
pubmed: 21606441
Cell Death Dis. 2017 Feb 2;8(2):e2585
pubmed: 28151478
Drugs. 2016 Mar;76(3):405-11
pubmed: 26846321
Annu Rev Biochem. 1998;67:425-79
pubmed: 9759494
Cell. 2017 May 18;169(5):792-806
pubmed: 28525752

Auteurs

Shiho Fukui (S)

Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan.

Kazunori Nagasaka (K)

Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan.

Yuko Miyagawa (Y)

Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan.

Ryoko Kikuchi-Koike (R)

Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan.

Yoshiko Kawata (Y)

Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan.

Ranka Kanda (R)

Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan.

Takayuki Ichinose (T)

Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan.

Takeru Sugihara (T)

Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan.

Haruko Hiraike (H)

Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan.

Osamu Wada-Hiraike (O)

Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan.

Yuko Sasajima (Y)

Department of Pathology, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan.

Takuya Ayabe (T)

Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan.

Classifications MeSH